News

Ovarian cancer expert Kelly McCann, MD, PhD, discusses the process of DNA damage and repair, resistance to PARP inhibitors, and rational combination strategies to overcome resistance.

Magtrace and Sentimag Magnetic Localization System, which uses magnetic detection to identify sentinel lymph nodes for surgical removal in women undergoing mastectomy for breast cancer, has gained approval from the FDA.

In an interview with&nbsp;<em>Targeted Oncology</em>, Panagiotis A.&nbsp; Konstantinopoulos, MD, director of Translational Research, Gynecologic Oncology Program at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, discussed the findings from the TOPACIO trial for patients with platinum-sensitive ovarian cancer. He also highlights the outlook for immunotherapy in gynecologic cancers and what the next steps are moving forward.

The primary endpoint of the phase III ALTA-1L trial has been met, as brigatinib was found to reduce the risk of&nbsp;disease progression or death versus crizotinib in adult patients with locally advanced or metastatic <em>ALK</em>-positive non&ndash;small cell lung cancer who had not received a prior ALK inhibitor,&nbsp;Takeda Pharmaceutical Company, the manufacturer of brigatinib, has announced.

In an interview with&nbsp;<em>Targeted Oncology</em>, Paul G. Richardson, MD,&nbsp;clinical program leader and director of Clinical Research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute,&nbsp;discussed the results from the OPTIMISMM trial. He also shared his insight on the significance of these findings and what he expects to see in the future for this patient population.

The addition of bortezomib to rituximab as a maintenance therapy following consolidative autologous hematopoietic stem cell transplantation may improve disease-free survival and overall survival in patients with mantle cell lymphoma, results of a small phase II study suggest.

Sagar Lonial, MD, details&nbsp;optimal sequencing techniques for patients with relapsed/refractory myeloma in a presentation during the 2018 Pan Pacific Lymphoma Conference.

Jacqueline D. Barrientos, MD, MS,&nbsp;discusses the current treatment landscape for CLL. She also highlights some of the biggest challenges for physicians and gave her insight on how to move forward in the field.

The R² regimen of lenalidomide (Revlimid) with&nbsp;rituximab (Rituxan) significantly improved progression-free survival compared with&nbsp;rituximab monotherapy in the&nbsp;treatment of patients with relapsed/refractory indolent lymphoma, meeting the primary endpoint of the phase III AUGMENT trial, Celegene,&nbsp;the manufacturer of lenalidomide, has announced.

Filgrastim-aafi, a filgrastim biosimilar, has been approved by the FDA to treat side effects associated with&nbsp;cancer treatment, including febrile neutropenia and severe neutropenia, according to an announcement from Pfizer, the manufacturer of the biosimilar.

Anthony R. Mato, MD, MSCE,&nbsp;discusses the next steps for umbralisib and the biggest challenges still facing patients with CLL.

Sham Mailankody, MBBS,&nbsp;discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options.

According to findings from the&nbsp;phase III IMpower132 study, the addition of atezolizumab to pemetrexed and cisplatin or carboplatin reduced the risk of disease progression or death compared with chemotherapy alone in patients with&nbsp;advanced nonsquamous non&ndash;small cell lung cancer.

Ivosidenib (Tibsovo) has been granted approval by the FDA for the treatment of&nbsp;adult patients with relapsed/refractory <em>IDH1</em>-mutant acute myeloid leukemia.

Sarah Holstein, MD, PhD,&nbsp;discusses new approaches to induction therapy for patients with multiple myeloma.

Alexander Drilon, MD, discusses the data currently available with targeting gene fusions, and shares insight into what is on the horizon in this area.

Atezolizumab (Tecentriq) has been granted a breakthrough therapy designation by the FDA for use in combination with&nbsp;bevacizumab (Avastin) as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma.

The combination of ibrutinib (Imbruvica) and rituximab (Rituxan) produced durable remissions in patients with relapsed/refractory mantle cell lymphoma, according to 4-year follow-up results from a single-arm phase II clinical trial.

Maintenance rituximab improved progression-free survival and overall survival following induction chemoimmunotherapy for&nbsp;patients with mantle cell lymphoma, according to results of a recent meta-analysis.<br /> &nbsp;

A biologics license application for sacituzumab govitecan has been granted a priority review by the FDA&nbsp;for the treatment of patients with metastatic triple-negative breast cancer following at least 2 prior therapies for metastatic disease, Immunomedics, the manufacturer of the antibody-drug conjugate, has announced.

Upfront&nbsp;ribociclib (Kisqali) has been granted approval by the FDA&nbsp;for use in combination with an aromatase inhibitor (AI) for the treatment of pre/perimenopausal or postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer.&nbsp;Additionally, ribociclib was approved in combination with fulvestrant for postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer.

Patients aged &ge;62 years with melanoma were more likely to respond to treatment with pembrolizumab than younger patients, according to results published in <em>Clinical Cancer Research. </em>Investigators at The Wistar Institute in Philadelphia concluded that the risk for progression following anti&ndash;PD-1 therapy declined by 13% with each decade of life.

Richard Kim, MD, recently shared his treatment considerations and decisions he makes when treating patients with hepatocellular carcinoma and colorectal cancer. Kim explained his treatment decisions based on 2 gastrointestinal case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives program.

Sumanta Kumar Pal, MD,&nbsp;sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

Now that chimeric antigen receptor T-cell therapies have received FDA approval for diffuse large B-cell lymphoma (DLBCL) after moving quickly through early phase clinical trials, research is now exploring ways to&nbsp;shift these agents earlier in the treatment paradigm, according to a discussion at the 2nd Annual Live Medical Crossfire on Hematologic Malignancies.

The&nbsp;Centers for Medicare &amp; Medicaid Services has proposed a slate of changes that would reduce payment for some forms of patient evaluation and management (E/M) and reduce the payment margin over wholesale acquisition cost for Medicare Part B drugs.

While the approval of new agents represents a great step forward in the treatment of&nbsp;chronic lymphocytic leukemia (CLL), physicians are now challenged with how to best utilize these new treatment options,&nbsp;according to a presentation by Anthony Mato, MD, MSCE, at the 2nd Annual Live Medical Crossfire: Hematologic Malignancies.

According to Pfizer and Astellas, the codevelopers of&nbsp;enzalutamide (Xtandi), the agent has been approved by the FDA for treatment of patients with nonmetastatic castration-resistant prostate cancer.

Sunitinib alone was noninferior for median overall survival compared with sunitinib plus cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma, according to findings from the phase III noninferiority CARMENA trial.

Michael Wang, MD, discusses what he hopes to find in the ZUMA-2 trial and his belief that MCL can be cured in his lifetime.